Loading clinical trials...

Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer

A Phase II Evaluation of Thalidomide (NSC #66847, IND 48832) in the Treatment of Recurrent of Persistent Endometrial Carcinoma

NCT00025467•National Cancer Institute (NCI)

View on ClinicalTrials.gov

Summary

Phase II trial to study the effectiveness of thalidomide in treating patients who have recurrent or persistent endometrial cancer. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor

Detailed Description

OBJECTIVES: I. Determine the antitumor cytostatic activity of thalidomide, in terms of 6-month progression-free survival, in patients with recurrent or persistent endometrial carcinoma. II. Determine the nature and degree of toxicity of this drug in these patients. III. Determine the partial and complete response rates in patients treated with this drug. IV. Determine the duration of progression-free and overall survival in patients treated with this drug. V. Determine the effect of this drug on initial performance status and histological grade in these patients. OUTLINE: This is a multicenter study. Patients receive oral thalidomide once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

Eligibility

Age

All ages

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Histologically confirmed endometrial carcinoma
•* Recurrent or persistent (refractory to curative therapy or established treatment)
•* No sarcomas
•At least 1 unidimensionally measurable lesion
•* At least 20 mm by conventional techniques, including palpation, plain x-ray, CT scan, or MRI
•* At least 10 mm by spiral CT scan
•At least 1 target lesion outside the area of prior radiotherapy
•Received 1 prior chemotherapy regimen for endometrial carcinoma
•* Initial treatment may include high-dose therapy, consolidation, or extended therapy
•* No more than 1 additional cytotoxic regimen for recurrent or persistent disease
+34 more criteria

Locations (1)

Gynecologic Oncology Group

Philadelphia, Pennsylvania, United States

Key Dates

Start Date

September 1, 2001

Primary Completion Date

July 1, 2007

Last Updated

January 24, 2013

Enrollment

ACTUAL participants

Conditions

Endometrial AdenoacanthomaEndometrial AdenocarcinomaEndometrial Adenosquamous Cell CarcinomaEndometrial Clear Cell CarcinomaEndometrial Papillary Serous CarcinomaRecurrent Endometrial Carcinoma

Interventions

thalidomide

DRUG

laboratory biomarker analysis

OTHER

Surgical and Obstetric Outcomes in Endometrial Adenocarcinoma and Atypical Endometrial Hyperplasia With Conservative Treatment

NCT07077876

Endometrial AdenocarcinomaEndometrial Hyperplasia+2 more

View study

ACTIVE_NOT_RECRUITINGPHASE2

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

NCT03660826

Endometrial AdenocarcinomaEndometrial Mixed Cell Adenocarcinoma+4 more

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 24, 2013Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer

Inclusion Criteria

Surgical and Obstetric Outcomes in Endometrial Adenocarcinoma and Atypical Endometrial Hyperplasia With Conservative Treatment

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Universal Endometrial Cancer DNA Sequencing for Detection of Lynch Syndrome and Personalized Care

Prognosis of METTL-14 in Endometrial Carcinoma

Assisted Exercise in Obese Endometrial Cancer Patients

Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer